SCHEMBL6170663

SCHEMBL6170663

Cc1cc([N+](=O)[O-])ccc1-c1cnco1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.49
TDP1 Q9NUW8 3/20 0.49
TSHR P16473 2/20 0.49
CYP3A4 P08684 3/20 0.46
IMPDH2 P12268 2/20 0.46
IMPDH1 P20839 2/20 0.46
AAK1 Q2M2I8 2/20 0.45
NPBWR1 P48145 2/20 0.40
PTPRC P08575 1/20 0.40
S100A4 P26447 1/20 0.40
HTT P42858 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
PKM P14618 2/20 0.39
MAPT P10636 2/20 0.39
GAA P10253 2/20 0.39
KDM4E B2RXH2 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30298789 1.00 ALDH1A1 (0.49) ALDH1A1TDP1TSHRCYP3A4IMPDH2
SCHEMBL12907860 0.88 ALDH1A1 (0.49) ALDH1A1TDP1TSHRCYP3A4IMPDH2
SCHEMBL8347590 0.84 GPR35 (0.47) ALDH1A1TDP1TSHRCYP3A4IMPDH2
SCHEMBL5777364 0.82 IMPDH2 (0.45) ALDH1A1TDP1CYP3A4IMPDH2IMPDH1
SCHEMBL16371752 0.82 CYP3A4 (0.45) ALDH1A1TDP1TSHRCYP3A4IMPDH2
SCHEMBL30292047 0.82 MAPT (0.53) ALDH1A1IMPDH2IMPDH1AAK1NPBWR1
SCHEMBL6224045 0.82 MAPT (0.53) ALDH1A1IMPDH2IMPDH1AAK1NPBWR1
SCHEMBL6170216 0.82 AAK1 (0.55) ALDH1A1TDP1CYP3A4IMPDH2IMPDH1
SCHEMBL5774602 0.82 AAK1 (0.45) ALDH1A1TDP1CYP3A4IMPDH2IMPDH1
SCHEMBL30292049 0.82 IMPDH2 (0.45) ALDH1A1TDP1CYP3A4IMPDH2IMPDH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3902798-B1 N-(4-(OXAZOL-5-YL)PHENYL)CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES ENDOGENA THERAPEUTICS INC (US) 2023-12-20 EP disclosed
US-20230322749-A1 NEW COMPOUNDS AND THEIR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT AND/OR PREVENTION OF DISEASES INVOLVING THE RETINAL PIGMENT EPITHELIUM ENDOGENA THERAPEUTICS, INC. (US) 2023-10-12 US disclosed
CN-115916192-A Novel compounds and their use as therapeutically active substances for the treatment and/or prophylaxis of diseases in which the retinal pigment epithelium is involved 内生疗法公司 2023-04-04 CN disclosed
US-20220089583-A1 N-(4-(OXAZOL-5-YL)PHENYL) CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES ENDOGENA THERAPEUTICS, INC. (US) 2022-03-24 US disclosed
WO-2021257092-A1 NEW COMPOUNDS AND THEIR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT AND/OR PREVENTION OF DISEASES INVOLVING THE RETINAL PIGMENT EPITHELIUM ENDOGENA THERAPEUTICS, INC. (US) 2021-12-23 WO disclosed
EP-3902798-A1 N-(4-(OXAZOL-5-YL)PHENYL)CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES Endogena Therapeutics, Inc. (US) 2021-11-03 EP disclosed
CN-113227086-A N- (4- (oxazol-5-yl) phenyl) chroman-3-carboxamide derivatives and related compounds as stimulators of production of retinal precursor cells for the treatment of neuroretinal diseases 内生疗法公司 2021-08-06 CN disclosed
WO-2020140050-A1 N-(4-(OXAZOL-5-YL)PHENYL)CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES ENDOGENA THERAPEUTICS, INC. (US) 2020-07-02 WO disclosed
US-7205324-B2 Inhibitors of IMPDH enzyme BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-17 US disclosed
EP-1126843-A4 COMPOUNDS DERIVED FROM AN AMINE NUCLEUS THAT ARE INHIBITORS OF IMPDH ENZYME BRISTOL MYERS SQUIBB CO (US) 2005-06-15 EP disclosed
US-6399773-B1 AUTOIMMUNE DISEASE; TRANSPLANTING ORGANS BRISTOL-MYERS SQUIBB CO. 2002-06-04 US disclosed
EP-1126843-A1 COMPOUNDS DERIVED FROM AN AMINE NUCLEUS THAT ARE INHIBITORS OF IMPDH ENZYME BRISTOL-MYERS SQUIBB COMPANY (US) 2001-08-29 EP disclosed
WO-2000025780-A1 COMPOUNDS DERIVED FROM AN AMINE NUCLEUS THAT ARE INHIBITORS OF IMPDH ENZYME BRISTOL-MYERS SQUIBB COMPANY (US) 2000-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322749-A1 NEW COMPOUNDS AND THEIR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT AND/OR PREVENTION OF DISEASES INVOLVING THE RETINAL PIGMENT EPITHELIUM ALDH1A2, NR2E3, RB1 ALDH1A1 462/4885TDP1 2441/4885TSHR 303/4885
US-20220089583-A1 N-(4-(OXAZOL-5-YL)PHENYL) CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES NR2E3, GFRA2, ALDH1A2 ALDH1A1 1885/4885TDP1 3901/4885TSHR 81/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.